This motivated the realization of this study with the aim to evaluate the non-inferiority and potential superiority of tadalafil cream, a topically administered PDE5 inhibitor, in comparison to oral tadalafil, an orally administered PDE5 inhibitor (tadalafil), for the treatment of erectile dysfunction in terms of avoiding systemic effects. The gene discussed is PDE5A; the disease is erectile dysfunction.